Prognostic value of ACE, BDKRB2, SLCO1B1, and ABO gene polymorphisms in the treatment of essential hypertension with a combination of enalapril and lercanidipine
Introduction. Insufficient efficacy of antihypertensive therapy remains the leading cause of cardiovascular complications development. Identifying pharmacogenetic predictors of treatment efficacy is a pressing issue in personalized medicine.Yu.Yu. Kupriyanov, I.V. Sychev, V.S. Marmuleva, S.N. Tuchkova, A.V. Lapshtaeva, L.N. Goncharova, K.B. Mirzaev, D.A. Sychev
Objective: To evaluate the impact of ACE, BDKRB2, SLCO1B1, and ABO gene polymorphisms on the risk of nonfatal cardiovascular events and long-term survivability in patients with essential hypertension.
Material and methods. An open-label, prospective, observational cohort study was performed involving 159 patients with essential hypertension receiving long-term treatment with a combination of enalapril and lercanidipine. The follow-up period was 5 years. SLCO1B1, ACE, ABO, and BDKRB2 gene polymorphisms were assessed using polymerase chain reaction. The primary endpoint was the incidence of nonfatal cardiovascular events due to treatment failure at years 1 and 3.
Results. In the studied cohort (n = 159, 83.1% females, median age 64.0 years), nonfatal cardiovascular events occurred in 3.77% of patients at year 1 and in 16.35% at year 3. Univariate analysis revealed that carriage of the CC genotype of the SLCO1B1 gene (rs4149056) demonstrated a trend toward an increased relative risk (RR) of nonfatal events at 3 years (RR 1.861; 95% CI: 0.599–5.778). However, in the multivariate Cox regression model, the effect of this factor reached statistical significance (p = 0.023). An association with ABO gene (rs495828) was also found for this endpoint: GG genotype was protective (OR 0.416; 95% CI: 0.198–0.877; p = 0.021). Five-year overall (22.64%) and cardiovascular (19.50%) mortality were not statistically significantly associated with the studied polymorphisms. No adverse events were recorded.
Conclusion. The association of ABO gene polymorphism (rs495828) with the medium-term risk of treatment failure was confirmed, as well as the independent prognostic value of the SLCO1B1 gene (rs4149056), taking into account multivariate adjustment. The impact of these markers on long-term survivability has not been established.
Keywords
References
- Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223–37.
PMID: 32024986. PMCID: PMC7998524. https://doi.org/10.1038/s41581-019-0244-2
- Kovesdy CP. Epidemiology of chronic kidney disease: An update 2022. Kidney Int Suppl (2011). 2022;12(1):7–11.
PMID: 35529086. PMCID: PMC9073222. https://doi.org/10.1016/j.kisu.2021.11.003
- Ferri N, Corsini A, Pontremoli R. Antihypertensive treatment with calcium channel blockers and renal protection: Focus on lercanidipine and lercanidipine/enalapril. Eur Rev Med Pharmacol Sci. 2022;26(20):7482–92.
PMID: 36314318. https://doi.org/10.26355/eurrev_202210_30018. Erratum in: Eur Rev Med Pharmacol Sci. 2022;26(22):8204. https://doi.org/10.26355/eurrev_202211_30347
- Hajdys J, Fularski P, Leszto K, Majchrowicz G, Stabrawa M, Młynarska E, et al. New insights into the nephroprotective potential of lercanidipine. Int J Mol Sci. 2023;24(18):14048.
PMID: 37762350. PMCID: PMC10531189. https://doi.org/10.3390/ijms241814048
- Masilela C, Pearce B, Ongole JJ, Adeniyi OV, Johnson R, Benjeddou M. Cross-sectional study of the association of 5 single nucleotide polymorphisms with enalapril treatment response among South African adults with hypertension. Medicine (Baltimore). 2021;100(46):e27836.
PMID: 34797313. PMCID: PMC8601271. https://doi.org/10.1097/MD.0000000000027836
- Altoum SM, Al-Mahayri ZN, Ali BR. Antihypertensives associated adverse events: A review of mechanisms and pharmacogenomic biomarkers available evidence in multi-ethnic populations. Front Pharmacol. 2023;14:1286494.
PMID: 38108069. PMCID: PMC10722273. https://doi.org/10.3389/fphar.2023.1286494
- Knezevic S, Filippi-Arriaga F, Belancic A, Bozina T, Mrsic-Pelcic J, Vitezic D. Metabolic syndrome drug therapy: The potential interplay of pharmacogenetics and pharmacokinetic interactions in clinical practice: A narrative review. Diabetology. 2024;5(4):406–29.
https://doi.org/10.3390/diabetology5040031
- Agostini LDC, Silva NNT, Belo VA, Luizon MR, Lima AA, da Silva GN. Pharmacogenetics of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) in cardiovascular diseases. Eur J Pharmacol. 2024;981:176907.
PMID: 39154825. https://doi.org/10.1016/j.ejphar.2024.176907
- Luo JQ, He FZ, Luo ZY, Wen JG, Wang LY, Sun NL, et al. Rs495828 polymorphism of the ABO gene is a predictor of enalapril-induced cough in Chinese patients with essential hypertension. Pharmacogenet Genomics. 2014;24(6):306–13.
PMID: 24743543. https://doi.org/10.1097/FPC.0000000000000050
- Borghi C, Santi F. Fixed combination of lercanidipine and enalapril in the management of hypertension: Focus on patient preference and adherence. Patient Prefer Adherence. 2012;6:449–55.
PMID: 22791982. PMCID: PMC3393122. https://doi.org/10.2147/PPA.S23232. Erratum in: Patient Prefer Adherence. 2013;7:801. https://doi.org/10.2147/PPA.S47439
- Antza C, Stabouli S, Kotsis V. Combination therapy with lercanidipine and enalapril in the management of the hypertensive patient: An update of the evidence. Vasc Health Risk Manag. 2016;12:443–51.
PMID: 27895487. PMCID: PMC5118038. https://doi.org/10.2147/VHRM.S91020
- Derosa G, Bonaventura A, Romano D, Bianchi L, Fogari E, D’Angelo A, Maffioli P. Effects of enalapril/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients. J Clin Pharm Ther. 2014;39(3):277–85.
PMID: 24635387. https://doi.org/10.1111/jcpt.12139
- Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, et al. The Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms. Clin Pharmacol Ther. 2022;111(5):1007–21.
PMID: 35152405. PMCID: PMC9035072. https://doi.org/10.1002/cpt.2557
- Flaten HK, Monte AA. The pharmacogenomic and metabolomic predictors of ACE inhibitor and angiotensin II receptor blocker effectiveness and safety. Cardiovasc Drugs Ther. 2017;31(4):471–82.
PMID: 28741243. PMCID: PMC5727913. https://doi.org/10.1007/s10557-017-6733-2
- White M, Lepage S, Lavoie J, De Denus S, Leblanc MH, Gossard D, et al. Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure. J Card Fail. 2007;13(2):86–94.
PMID: 17395047. https://doi.org/10.1016/j.cardfail.2006.10.013
About the Authors
Yuri Yu. Kupriyanov, MD, senior lecturer at the Department of infectious diseases (with courses in epidemiology, phthisiology, and dermatovenereology) of the Medical Institute, N.P. Ogarev Mordovia State University, Saransk, Russian Federation.E-mail: bektype@gmail.com
ORCID: https://orcid.org/0000-0002-4993-5515
Ivan V. Sychev, MD, researcher at World-Class Research Center “Center for Predictive Genetics, Pharmacogenetics and Personalized Therapy”, Academician B.V. Petrovsky National Research Centre of Surgery, Moscow, Russian Federation.
E-mail: sychev_iv@bk.ru
ORCID: https://orcid.org/0000-0003-0227-2651
Veronika S. Marmuleva, student of Ivanovo State Medical University, Ivanovo, Russian Federation.
E-mail: nauka.mvs@gmail.com
ORCID: https://orcid.org/0009-0003-2886-197X
Svetlana N. Tuchkova, MD, researcher at Academician B.V. Petrovsky National Research Centre of Surgery; researcher at Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation.
E-mail: svetlana.tuch1998@gmail.com
ORCID: https://orcid.org/0009-0001-2744-2752
Anna V. Lapshtaeva, MD, PhD (Medicine), associate professor, associate professor of the Department of immunology, microbiology and virology (with a course in clinical immunology and allergology), N.P. Ogarev Mordovia State University, Saransk, Russian Federation.
E-mail: av_lapshtaeva@mail.ru
ORCID: https://orcid.org/0000-0003-4828-2476
Lyudmila N. Goncharova, MD, Dr. Sci. (Medicine), professor, professor of the Department of faculty therapy (with a course in physiotherapy and therapeutic exercise), N.P. Ogarev Mordovia State University, Saransk, Russian Federation.
E-mail: glnsm@mail.ru
ORCID: https://orcid.org/0000-0002-4324-9071
Karin B. Mirzaev, MD, Dr. Sci. (Medicine), associate professor, deputy head of World-Class Research Center “Center for Predictive Genetics, Pharmacogenetics and Personalized Therapy”, Academician B.V. Petrovsky National Research Centre of Surgery; professor of the Department of clinical pharmacology and therapy named after academician B.E. Votchal, Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation.
E-mail: karin05doc@yandex.ru
ORCID: https://orcid.org/0000-0002-9307-4994
Dmitry A. Sychev, MD, Dr. Sci. (Medicine), professor, academician of RAS, scientific director of World-Class Research Center “Center for Predictive Genetics, Pharmacogenetics and Personalized Therapy”, Academician B.V. Petrovsky National Research Centre of Surgery; head of the Department of clinical pharmacology and therapy named after academician B.E. Votchal, Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation.
E-mail: dimasychev@mail.ru
ORCID: https://orcid.org/0000-0002-4496-3680



